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a  b  s  t  r  a  c  t
Background:  Human  papillomavirus  (HPV)  vaccination  offers  potential  for primary  prevention  of  HPV-
related  pre-cancers  and  cancers  as demonstrated  in  clinical  trials.  Mathematical  models  have  estimated
the  potential  real-life  impact  of  vaccination  on the  burden  of cervical  cancer  (CC).  However,  these  are
restricted  to  evaluations  in a limited  number  of countries.
Methods: Potential  decline  in  CC  cases  and deaths  with  the  AS04-adjuvanted  HPV-16/18  vaccine  of young
girls  naïve  to  HPV,  was estimated  at steady-state  (vaccine  coverage:  0–100%)  based  on  clinical  trial  and
country-speciﬁc  incidence  data.  Data on  vaccine  efﬁcacy  were  taken  from  the  end  of study  PATRICIA  trial
of  the AS04-adjuvanted  HPV-16/18  vaccine.  The  numbers  of  cases  and  deaths  due  to  HPV-16/18  were
estimated  and  compared  with  those  due  to any  HPV  type  to  estimate  the  additional  cases  prevented.  This
difference  estimates  CC cases  and  deaths  avoided  due  to protection  against  non-vaccine  HPV  types.  Cost-
offsets  due  to reductions  in  CC  treatment  were  estimated  for ﬁve  countries  (Brazil,  Canada,  Italy,  Malaysia
and  South  African  Republic)  using  country-speciﬁc  unit  cost  data.  Additionally,  cervical  intraepithelial
neoplasia  grade  2 or  3 (CIN2/3)-related  burden  (cases  and  treatment  costs)  prevented  by  vaccination
were  estimated  for  two  countries  (Italy  and  Malaysia).
Results: HPV  vaccination  could  prevent  a substantial  number  of CC  cases  and  deaths  in countries  world-
wide,  with  associated  cost-offsets  due  to  reduced  CC treatment.  Cross-protection  increased  the  estimated
potential  number  of CC  cases  and  deaths  prevented  by 34  and  18%  in  Africa  and  Oceania,  respectively.
Moreover,  vaccination  could  result  in a substantial  reduction  in the  number  of CIN2/3  lesions  and  asso-
ciated  costs.
Conclusion:  HPV  vaccination  could  reduce  the  burden  of  CC  and  precancerous  lesions  in  countries  world-
wide,  part of  disease  burden  reduction  being  related  to  protection  against  non  HPV-16/18  related  types.
 201©
. IntroductionCervical cancer (CC) is the third most common cancer in women,
ith an estimated 530,000 new cases worldwide in 2008 [1].
espite screening, the burden of CC remains high, with 275,000
Abbreviations: CC, cervical cancer; CIN, cervical intraepithelial neoplasia; HPV,
uman papillomavirus; TVC, total vaccinated cohort; HSIL, high-grade squamous
ntraepithelial  lesion; ICO, Institut Català d’Oncologia; VE, vaccine efﬁcacy; WHO,
orld Health Organization; LEEP, loop electrosurgical excision procedure; LLETZ,
arge loop excision of the transformation zone.
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deaths estimated for 2008 [1]. The burden of CC varies considerably
between countries, with 85% of cases and 88% of deaths occurring
in developing nations [1,2]. Human papillomavirus (HPV) is estab-
lished as a necessary cause of CC, with HPV identiﬁed in 99.7% of
CC cases worldwide [3]. The two HPV types most commonly asso-
ciated with CC are HPV types 16 and 18. However, approximately a
quarter of CC cases are associated with other oncogenic HPV types
and therefore, impose a substantial health burden [4].
Precancerous lesions also known as cervical intraepithelial
neoplasia (CIN) impose a health burden beyond that of CC itself, par-
ticularly in countries with well-established screening programmes
where CIN lesions are more likely to be detected [5]. High-grade
cervical intraepithelial neoplasia (CIN2/3), when diagnosed, results
Open access under CC BY-NC-ND license.in conisation or surgical excision to remove the lesion, as per con-
sensus guidelines for management of CIN2/3 [6].
Vaccination against oncogenic HPV infection offers the poten-
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PV vaccines are currently available: a HPV-6/11/16/18 vaccine
Gardasil®, Merck/Sanoﬁ-Pasteur) and a HPV-16/18 vaccine with
djuvant System 04 (AS04) (Cervarix®, GlaxoSmithKline Vaccines).
he PApilloma TRIal against Cancer In young Adults (PATRICIA)
s the largest trial conducted so far with a licenced HPV vac-
ine. This trial assessing the HPV-16/18 AS04-adjuvanted vaccine
nrolled 18,729 healthy women aged 15–25 years irrespective of
heir baseline HPV DNA status [7,8]. Data from the end-of-study
nalysis of the PATRICIA trial showed that the AS04-adjuvanted
PV-16/18 vaccine demonstrated 100% efﬁcacy against CIN3+
esions associated with HPV 16/18 and further had an overall vac-
ine efﬁcacy (VE) of 93.2% against CIN3+ lesions irrespective of
PV type in the HPV-naïve1 total vaccinated cohort (TVC) after a
ollow-up time up to 48 months [9]. These results demonstrated
hat protection against non-vaccine HPV types is present, with
r without co-infection with HPV 16/18 [9,10]. These ﬁndings
uggest that this vaccine could offer important health bene-
ts in reducing precancerous lesions and CC cases beyond that
xpected from the prevention of lesions caused by HPV types-16/18
lone.
The objective of the present study was to estimate the potential
eal life impact of the AS04-adjuvanted HPV-16/18 vaccine on CC
ases and deaths at country level in all WHO  reported countries dif-
erentiating number of cases potentially prevented irrespective of
he causative HPV type as well as cases prevented causally related to
PV-16/18. These number of cases and deaths were subsequently
rouped by continent. Additionally, potential reduction in the treat-
ent costs of CC in ﬁve countries located in ﬁve different regions
nd the potential effect of vaccination on the burden and cost of
recancerous lesions in two other countries (one from Europe and
ne from Asia) was evaluated.
.  Materials and methods
.1.  Potential impact of vaccination on the number of CC cases
nd  deaths prevented over a one-year period
.1.1. Country speciﬁc CC cases and deaths prevented irrespective
f HPV type
The  number of CC cases and deaths, irrespective of HPV type,
otentially prevented annually by HPV vaccination at steady-state
once the entire susceptible population has been vaccinated prior
o sexual debut and thus the total population is assumed to beneﬁt
rom vaccination) for each country was estimated by multiplying
he reported annual number of cases by vaccine coverage and VE
s a proxy for vaccine effectiveness as follows:
ases prevented = annual number of cases × coverage
× vaccine effectiveness
The annual number of cases and deaths was speciﬁc to each
ountry, using projections for 2008 from the International Agency
or Research in Cancer [1].
The proxy vaccine effectiveness irrespective of HPV type used
gainst CC cases and deaths was 93% (95% CI:79–99%). It is based
n the most recent data on the HPV-16/18 AS04-adjuvanted VE
gainst CIN3+ irrespective of HPV type in the HPV- naïve1 TVC
rom the end-of-study results from the PATRICIA trial [9]. The
fﬁcacy observed in this population is thought to be represen-
ative of the VE among the primary target population for HPV
accination programmes in many countries worldwide, i.e. girls
re-sexual debut [11,12]. Vaccination was assumed to offer lifetime
rotection.ne 32 (2014) 733– 739
2.1.2. Country speciﬁc CC cases and deaths prevented causally
related  to HPV-16/18
The  number of cases prevented for each country that could be
attributed to protection against HPV-16/18 alone was estimated by
multiplying the annual number of CC cases and deaths by vaccine
coverage and the expected vaccine effectiveness against HPV-16/18
related-CC cases and deaths. The HPV-16/18 related effectiveness
was estimated using country-speciﬁc data of the proportion of CC
cases attributable to HPV-16/18 multiplied by the reported vaccine
efﬁcacy against HPV-16/18-related CC.
Vaccine efﬁcacy of 100% against HPV-16/18-related CC was
used based on the AS04-adjuvanted HPV-16/18 VE against CIN3+
causally related to HPV-16/18 in the HPV-naïve1 TVC from the
end-of-study data from the PATRICIA trial [9]. The distribution of
HPV-16/18 in CC cases speciﬁc for each country was taken from the
Institut Catala d’Oncologia (ICO) Information Centre on HPV and
cancer database [2], using a weighted distribution if the summed
distribution exceeded 100% (all HPV = 100%) or the unadjusted
distribution if the sum of the distribution did not exceed 100%.
Country-speciﬁc HPV distributions were used where available or
valid. Data were considered not valid when data for less than 7
HPV types were reported or the sum of the minimum and maxi-
mum number of samples for the determination of any of the HPV
type distribution was less than 100. For countries without country-
speciﬁc data, regional values when available or continental values
were used.
The  annual numbers of CC cases and deaths (irrespective of HPV
type and HPV-16/18-related) potentially prevented by HPV vacci-
nation at steady-state were tabulated for each individual country
for four scenarios of vaccine coverage i.e. 50, 70, 90 and 100%.
The  formulae below formally describes the calculations used.
CC  preventedirrespective = CC × VEirrespective × vac coverage
CC  preventedHPV−16/18 = CC × VE16/18 × %HPV16/18 × vac coverage
CC preventednon-HPV-16/18
= CC preventedirrespective − CC preventedHPV-16/18
with:
CC preventedirrespective = annual number of cc cases/deaths pre-
vented by vaccination irrespective of HPV type
CC preventedHPV-16/18 = annual number of CC cases/deaths pre-
vented by vaccination causally related to HPV-16/18 infection
CC  preventednon-HPV-16/18 = annual number of CC cases/deaths pre-
vented by vaccination not related to HPV-16/18 infection
CC  = country-speciﬁc annual incident number of CC cases/deaths
Vac coverage = HPV vaccination coverage
VEirrespective = 93% vaccine efﬁcacy irrespective of HPV type [9]
VE16/18 = 100% vaccine efﬁcacy against CC cases/deaths causally
related to HPV-16/18 infection [9]
2.1.3. Regional and worldwide CC cases and deaths prevented
The  CC cases and deaths prevented are graphically presented by
WHO continent. These were estimated by summing up all the CC
cases and deaths prevented of the countries constituting each of
the WHO  continents (i.e. Africa, America, Asia, Europe, Oceania). A
worldwide estimate was made by summing up the results for all
countries for vaccination coverage levels ranging from 0 to 100%.
The number of CC cases and deaths averted not causally related
to HPV-16/18 infection were estimated at three possible scenarios
of vaccination coverage (50, 70 and 90%) for each WHO  continent
and worldwide by taking the difference between the CC cases and
deaths prevented that are causally related to HPV-16/18 and the
CC cases prevented by vaccination irrespective of HPV type for all
countries in the analysis.
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Table 1
Input  data for cost-offset analysis.
Parameter Mexico Canada Germany Thailand South Africa
Estimated survival time [1]
Annual number of incident
CC  cases
10,186 1419 4440 9997 5743
Expected  5-year cumulative
incidence
50,930  7095 22,200 49,985 28,715
5-year  CC prevalence 34,294 5149 14,745 35,338 15,922
Proportion  alive after 5 years 0.673  0.726 0.664 0.707 0.554
Average  survival time (years) 3.4 3.6 3.3 3.5 2.8
Unit  cost of CC treatment
Reported  unit costs and yeara MXP  81,478 (2006) [14] CAD 15,302 (2006) [15] EUR 12,342 (2006) [16,17] THB 170,275 (2009) [18] ZAR 35,360(2007) [19]
Unit costs updated to 2011
value  [20]a
MXP  100,994 CAD 16,809 EUR 13,448 THB 182,614 ZAR 46,254
lifetime  cost MXP 343,380 CAD 60,512 EUR  44,378 THB 639,149 ZAR 128,237
a





































Input  data for precancerous lesion analysis.
Parameter Italy Malaysia
Annual number of CIN2/3 11,976 [21] 592 [5]
% of HPV-16/18 in HSIL 48.7 (Italy) [2] 42.4 (Asia continent) [2]
Vaccine  efﬁcacy CIN2+ 64.9% [9]
Cost of CIN2/3 treatment EUR 992 [21] MYR  1558 [5]
Cost  of CIN2/3 treatment at
2011 values [20]
EUR 1019 MYR  1644
was assumed to be 100%, based on VE against CIN2+ causally related
to HPV-16/18 reported from the end-of-study from the PATRICIA
trial among the HPV-naïve1 TVC [9].Annual average treatment cost reported for all countries.
ote: MXP  - Mexican Pesos; CAD - Canadian Dollar; EUR - Euro; THB - Thai Baht; ZA
.1.4. CC-related cost-offset
In  ﬁve countries (Mexico, Canada, Germany, Thailand and South
frican Republic) the expected reduction in CC treatment costs
esulting from the cases potentially prevented by HPV vaccination
cost-offset) were estimated. One country among countries with
vailable data was randomly selected from each of the following
ontinents: Asia, Africa, Europe, South America and North America.
he total estimated cost-offset, from the healthcare payer perspec-
ive was calculated by multiplying the number of incident CC cases
revented by the country-speciﬁc estimated lifetime cost per case:
otal cost − offset = incident CC prevented × lifetime cost
For each of the ﬁve countries, the total cost-offset for CC cases
revented irrespective of the causative HPV type, CC prevented
ausally related to HPV-16/18 infection, and the difference between
hem, i.e. the additional cost-offset from protection against HPV
ypes other than HPV-16/18 was estimated. For comparison pur-
oses the cost-offset related to CC cases other than HPV-16/18
ere converted to international dollars using the 2011 purchase
ower parity conversion factor for gross domestic product based on
ata from the World Bank for each country [13]. For each analysis,
accination coverage was assumed to be 80%.
.1.4.1. Unit costs. Lifetime CC treatment costs, from a health-
are payer perspective, were obtained from published literature
14–19]. For each country in this cost analysis, the publications
eported average annual costs rather than lifetime costs. An approx-
mation of lifetime cost was obtained by multiplying the average
nnual cost by the estimated average survival time for patients with
ncident CC in each country over the 5 years post diagnosis. It was
ssumed that a cancer patient alive for 5 years post diagnosis is
ured and hence without any treatment and costs associated. The
verage survival time was estimated for each country using data
n the number of annual incident cases and estimates of 5 year
revalence reported by Globocan 2008 [1] as follows:
5 years prevalent cases/incident cases × 5) × 5
= average survival over the 5 years post diagnosisCosts for CC treatment were expressed in local currency and
pdated to 2011 values using the country-speciﬁc Consumer Price
ndex reported by the World Bank for each country [20]. Estimated
urvival times and lifetime costs are shown in Table 1.Note: CIN2/3 - Cervical intraepithelial neoplasia grade 2/3; HSIL - High-grade squa-
mous intraepithelial lesion; EUR - Euro; MYR  - Malaysian Ringgit.
2.2. Potential impact of HPV vaccination on high grade cervical
lesions
The potential annual effect of HPV vaccination on the burden
related to CIN 2/3 at vaccination steady state was  estimated in
two countries: Italy and Malaysia, randomly selected based on data
availability. The method used is identical to the one used to esti-
mate the vaccine impact on CC cases and deaths. The number of
CIN2/3 cases prevented with vaccination irrespective of HPV type,
the expected number of HPV-16/18 related CIN2/3 avoided by vac-
cination cases as well as the difference between the two were
estimated. Vaccination coverage was  assumed to be 80% in both
countries.
2.2.1. CIN2/3 cases prevented irrespective of HPV type
The  prevalent annual numbers of CIN2/3 lesions prior to the
introduction of vaccination for Italy and Malaysia were retrieved
from literature (Table 2) [5,21]. The vaccine effectiveness against
CIN2/3 lesions irrespective of HPV type was assumed at 64.9% based
on the VE reported against CIN2+ lesions, irrespective of HPV type in
the HPV-naïve1 TVC from the end-of-study results from the PATRI-
CIA trial [9].
2.2.2.  CIN2/3 cases prevented causally related to HVP-16/18
Vaccine effectiveness against CIN2/3 lesions related to HPV-
16/18 was estimated based on the effectiveness against HPV-16/18
CIN2/3 lesion and the proportion of CIN2/3 related to HPV-16/18.
The vaccine effectiveness against HPV-16/18-related CIN2/3 lesions1 TVC naïve: includes all vaccinated subjects who received at least one dose of
vaccine,  who  had normal cytology, were HPV DNA negative for 14 oncogenic HPV
types (including HPV-16 and HPV-18), and seronegative for HPV-16 and HPV-18 at
baseline.
















cFig. 1. Cervical cancer cases avoided by HPV vaccination at varying levels 
The proportion of CIN2/3 related to HPV type-16/18 was calcu-
ated based on the HPV-16/18 distribution reported for high-grade
ervical lesions in the ICO HPV Information Centre database for each
ountry [2] (Table 2).
.2.3.  CIN2/3-related cost-offset
The expected CIN2/3-related treatment costs potentially offset
y HPV vaccination was estimated assuming that 100% of CIN2/3
esions prevented by vaccination would be treated. The offset on
reatment costs was estimated by multiplying the number of cases
otentially prevented by the CIN2/3 treatment unit cost. For com-
arison purposes the cost-offset related CIN2/3 treatment other
han HPV-16/18 were converted to international dollars using 2011
urchase power parity conversion factor for gross domestic prod-
ct, based on data from the World Bank for each country [13]..2.3.1.  Unit cost. Unit costs for the treatment of CIN2/3 in each
ountry are shown in Table 2. Costs were expressed in local
urrency and updated to 2011 value using the country-speciﬁcerage in (a) Africa, (b) America, (c) Asia, (d) Europe, (e) Oceania (f) World.
Consumer Price Index reported by the World Bank for each country
[20].
3. Results
3.1. CC cases, deaths prevented and treatment costs-offset
Fig. 1 presents country level results grouped by WHO  continent
and worldwide of the estimated annual numbers of CC cases poten-
tially avoided by HPV vaccination at steady-state at varying levels
of vaccination coverage. Individual country estimates at four levels
of vaccination coverage (50, 70, 90 and 100%) are shown in Sup-
plementary File 1. In all ﬁve WHO  continents, numbers of cases
potentially prevented by vaccination was at least 18% greater in
the analyses including cases causally related to HPV irrespective of
type, compared with the cases causally related to HPV-16/18 infec-
tion only. The relative difference (i.e. the percentage increase of
cases avoided causally related to all HPV types vs. HPV-16/18 only)
was most pronounced in Africa (34%). Relative increase of number












pFig. 2. Cervical cancer deaths avoided by HPV vaccination at varying l
f cases avoided for other WHO  continents was 27% for America,
6% for Asia, 21% for Europe, 18% for Oceania and 27% worldwide.
A  similar pattern was observed for the estimated annual
umbers of CC deaths potentially prevented by HPV vaccination
Fig. 2). Similarly to CC cases prevented, the inclusion of CC deaths
revented irrespective of HPV type in the analysis increased by
t least 18% the estimated number of deaths potentially avoided,
ith the relative difference having the same values as for CC cases
able 3
ost-offset for cervical cancer treatment over one year at vaccine steady-state.
Parameter Mexico Canada 
CC cases avoided HPV-16/18 alone 5500 843 
Cost  avoided HPV-16/18 alone 1,870,281,833 MXN  51,443,667 C
CC  cases avoided irrespective of HPV type 7578 1056 
Cost  avoided irrespective of HPV type 2,576,832,748 MXN  64,391,131 C
Difference  in cost avoided (local currency) 706,550,915 MXN 12,947,464 C
Difference  in cost (2011, Int$) Int$ 86,289,462 Int$ 10,505,1
ote: MXP  - Mexican Pesos; CAD - Canadian Dollar; EUR - Euro; THB - Thai Baht; ZAR - S
apillomavirus.of coverage in (a) Africa, (b) America, (c) Asia, (d) Europe, (e) Oceania.
analysis.  Individual country estimates for the CC deaths potentially
prevented at four levels of vaccination coverage (50, 70, 90 and
100%) are shown in Supplementary File 2.
Table 3 shows the estimated annual cost-offset associated
with CC prevention at steady-state in Mexico, Canada, Germany,
Thailand and South African Republic. Including VE irrespective of
HPV type in the analysis increased the estimated cost-offset in all
ﬁve countries by at least 10 million Int$.
Germany Thailand South African Republic
2754 5903 2885
AD 122,994,317 EUR 3,810,735,886 THB 369,998,774 ZAR
3303 7439 4273
AD 147,522,853 EUR 4,802,146,849 THB 547,928,120 ZAR
AD 24,528,536 EUR 991,410,962 THB 177,929,347 ZAR
60 Int$ 30,575,717 Int$ 56,912,151 Itl$ 33,506,831
outh African Rand; Int$ - International Dollar; CC - Cervical cancer; HPV  - Human
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Table 4
CIN2/3 cases avoided, CIN2/3 treatment cost avoided and cost-offset over one year
at vaccine steady-state and 80% vaccination coverage rate.
Parameter Italy Malaysia
CIN 2/3 cases avoided
HPV  16/18 only 4665 201
Irrespective of HPV type 6218 307




HPV 16/18 only 4,753,635 EUR 330,444  MYR
Irrespective of HPV type 6,336,142 EUR 504,708 MYR
Difference (irrespective minus HPV
16/18 only)
1,582,507 EUR 174,264 MYR












































tote: Int$ - International Dollar; HPV - Human papillomavirus; CIN 2/3 - Cervical
ntraepithelial  lesions grade 2/3.
.2. CIN2/3 cases avoided and treatment cost-offset
Table 4 presents the estimated annual numbers of CIN2/3 cases
voided by HPV vaccination at steady-state in Italy and Malaysia.
he estimated vaccine impact on CIN2/3 cases, and treatment costs
verted were 33 and 53% higher in Italy and Malaysia respectively,
or the analysis irrespective of HPV type, compared with the esti-
ates for HPV-16/18 only.
. Discussion
The results presented here suggest that HPV vaccination of
oung girls naïve to HPV with the AS04-adjuvanted HPV-16/18 vac-
ine could reduce the number of CC cases and deaths in countries
orldwide, with the absolute number of CC cases and deaths and
ence, lives saved depending on the vaccination coverage achieved.
Additionally, we have attempted to quantify the impact of
rotection against HPV types other than HPV-16/18. Although
he vaccine was designed to target HPV-16/18, end-of-study data
rom the 4-year PATRICIA trial demonstrated efﬁcacy against non-
accine HPV types [10], and an overall VE against CIN3+ lesions of
3% irrespective of HPV type in the lesion in the HPV-naïve1 TVC
ohort [9]. We  have applied these data to the currently observed
isease burden in all WHO  reported countries to estimate the addi-
ional health beneﬁts of vaccination that accrue from protection
gainst HPV types other than HPV-16/18. When protection irre-
pective of HPV types was considered, the number of CC cases
nd deaths potentially prevented by vaccination was  at least 18%
arger than when only HPV-16/18 were considered. The increased
otential beneﬁt was seen across all ﬁve WHO  continents, and
as particularly pronounced in Africa, where non-HPV-16/18 cases
ccount for 17,125 cases prevented at 70% vaccination cover-
ge representing an additional 34% cases potentially prevented,
ompared with 272 cases additionally prevented in Oceania, rep-
esenting an additional 18% cases potentially prevented.
HPV vaccination also has the potential to reduce the morbidity
ssociated with precancerous lesions. Management of precancer-
us lesions detected by screening may  require surgical procedures,
uch as conisation. In countries with absent or poorly developed
ervical screening programmes, few precancerous lesions will be
etected and the health impact will mainly be observed when
ndetected lesions progress to symptomatic cancer. Conversely,
n countries with well-developed and effective screening pro-
rammes, many precancerous lesions are detected at an early stage
nd are usually treated before they progress to cancer, so the health
urden will tend to shift away from CC treatment towards pre-
ancerous lesion treatment. In some industrialised countries, the
conomic burden of precancerous lesions may  exceed or approach
he economic burden of CC. For example, a study of patients in ane 32 (2014) 733– 739
health  maintenance plan in the USA found that treatment of CC
accounted for 10% of healthcare expenditure on HPV-related cer-
vical disease and treatment of precancerous lesions accounted for
17% [22]. In Belgium, the total annual cost of CC treatment to the
healthcare payer was estimated at Euro 6.5 million and the annual
cost of precancerous lesions at Euro 1.97 million in a retrospective
study [23]. Other morbidities associated with treatment of pre-
cancerous lesions of the cervix avoidable by vaccination such as
increased risk of perinatal death and pre-term births should also
be considered [24,25].
To  our knowledge, this is the ﬁrst estimate of the potential
impact of HPV vaccination on CC cases and deaths to apply the
recent data on VE irrespective of HPV type causing the lesion
reported from the end-of-study data in the PATRICIA trial [9,10].
Thus, it builds on previous estimates of the potential health impact
of HPV vaccination by taking into account the most recent data
on protection against non-vaccine HPV types. In this analysis, we
extrapolated VE data from PATRICIA to Africa, thereby implicitly
assuming that VE would not differ between Africa and the regions
included in the trial. Recent study results in African girls and women
showed that immune responses were similar to those observed in
European populations thus strengthening our assumption [26].
Our  study has limitations. Although, we have used country-
speciﬁc data from WHO  databases to ensure consistency by the
use of the same data source, these estimates may  differ from local
epidemiological data of the countries. Second, our estimates are
derived at vaccine steady-state, which in a real-life setting will
need many years to be achieved. Consequently, the full poten-
tial of reduction in CC cases and deaths estimated here will need
time to be realised. However, the estimated potential reductions in
high-grade CIN could be observed earlier. For example, in Australia,
where a large catch up for the HPV vaccination programme was
put in place, a signiﬁcant reduction in the incidence of high-grade
lesions was observed within three years of introduction of the HPV
vaccination programme [27]. We  have also assumed that the cross-
protective effect of vaccination will have the same duration as
vaccine-type HPV. Recent data from an independently conducted
clinical trial reported persistence of cross-neutralizing antibody
titres 3 years after vaccination, suggesting that cross-reactive anti-
body responses are likely to persist long-term [29]. This was  further
corroborated by data from the follow-up of the phase II trial of
the AS04-adjuvanted HPV-16/18 vaccine have demonstrated cross-
reactive immune response that is sustained up to at least 7 years
post vaccination. This strengthens our assumption that the cross-
protective effect demonstrated in the PATRICIA trial may be of long
duration [28]. The estimated beneﬁts of vaccination could however
be less than projected, should the cross-protection be demon-
strated to wane over time. Lastly, our estimates did not take account
herd immunity effects, and thus we may  have underestimated the
potential effect of HPV vaccination.
5. Conclusion
Our evaluation estimates that vaccination of young girls naïve
to HPV with the AS04-adjuvanted HPV-16/18 vaccine could result
in reductions in the number of CC cases and deaths in countries
worldwide resulting in lives saved and CC-related cost-offsets. A
proportion of the estimated potential reduction relates to pro-
tection against non-HPV-16/18 related HPV types. Additionally,
prevention of precancerous lesions could reduce the morbidity
associated with these lesions and result in further cost-savings.Acknowledgements
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